Natera executive chairman Rabinowitz sells $3.4m in stock

Natera, Inc. (NTRA) Executive Chairman Matthew Rabinowitz sold 17,100 shares for $3.42 million at approximately $200 per share, near the company's 52-week high, executed under a Rule 10b5-1 trading plan ahead of its upcoming earnings report. Despite not yet being profitable and trading at a high Price/Book multiple of 21.83, Natera has delivered a 60.59% return over the past year, supported by recent positive clinical trial results in early cancer detection and minimal residual disease, leading several analysts like Canaccord Genuity, BTIG, and Piper Sandler to reiterate Buy ratings and raise price targets.

Analysis

Natera, Inc. (NTRA) Executive Chairman Matthew Rabinowitz executed a significant insider sale of 17,100 shares for $3.42 million on November 3, 2025, at prices near the 52-week high of $200.76. This transaction, conducted under a pre-arranged Rule 10b5-1 plan, occurred just two days prior to the company's upcoming earnings report. Despite the sale, Rabinowitz retains a substantial direct and indirect ownership of over 2.3 million shares.

The company exhibits robust liquidity with a current ratio of 3.72, yet remains unprofitable, reporting a diluted EPS of -$1.92. Natera's stock has delivered an impressive 60.59% return over the past year, leading to a high Price/Book multiple of 21.83, indicating a premium valuation based on future growth expectations rather than current profitability.

Recent positive clinical trial results are bolstering Natera's outlook, particularly in early cancer detection (PROCEED-CRC trial showing 22.5% sensitivity and 91.5% specificity for advanced adenomas) and minimal residual disease (MRD) with the Signatera test in muscle-invasive bladder cancer. This progress has led multiple firms, including Canaccord Genuity, BTIG, and Piper Sandler, to reiterate or raise their Buy/Overweight ratings and price targets, citing Natera's first-mover advantage and strong clinical data in molecular diagnostics.

Key Decisions for Investors

• Monitor Natera's upcoming earnings report for November 6 closely, as current high valuation metrics like the 21.83 Price/Book and lack of profitability (EPS -$1.92) suggest significant growth expectations are priced in.
• Evaluate the implications of the Executive Chairman's Rule 10b5-1 insider sale, understanding it was pre-planned but occurred near the 52-week high, while also noting his substantial remaining stake.
• Assess the long-term potential of Natera's advancements in early cancer detection and MRD, as these clinical successes and strong analyst endorsements (Canaccord Genuity, BTIG, Piper Sandler) are key drivers for its 60.59% annual return and future growth trajectory.